A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans

D Wilkes, P Rutland, L J Pulley, W Reardon, C Moss, J P Ellis, R M Winter, S Malcolm

Abstract
Mutations in the fibroblast growth factor receptor 2 (FGFR2) gene have previously been identified in Crouzon syndrome, an autosomal dominant condition involving premature fusion of the cranial sutures. Several different missense and other mutations have been identified in Crouzon syndrome patients, clustering around the third immunoglobulin-like domain. We report here the identification of a mutation in the transmembrane region of FGFR3, common to three unrelated patients with classical Crouzon syndrome and acanthosis nigricans, a dermatological condition associated with thickening and abnormal pigmentation of the skin. The mutation within the FGFR3 transcript was determined by direct sequencing as a specific ggc to gag transversion, resulting in an amino acid substitution ala391glu within the transmembrane region.

(J Med Genet 1996;33:744–748)

Keywords: Crouzon syndrome; acanthosis nigricans; fibroblast growth factor receptor 3 (FGFR3).

Several clinically distinct monogenic disorders present with craniosynostosis, the premature fusion of the skull bone sutures. Initially delineated purely on clinical grounds, several reports over the last year have identified the mutational basis of the phenotypes and posed new questions as to the mechanisms by which the resultant malformations arise. Initially described in Crouzon syndrome, mutations at the fibroblast growth factor receptor 2 (FGFR2) locus on chromosome 10 have since been identified in Apert and Jackson-Weiss syndromes.

A mutation in the related gene on chromosome 8, FGFR1, has been characterised in Pfeiffer syndrome, but locus heterogeneity in this syndrome was established with the observation of Pfeiffer syndrome cases having mutations at the FGFR2 locus. More than three such mutations, all resulting in the substitution of cys342, have been identified in both Crouzon and Pfeiffer syndrome cases and the factors governing the development of these clinically distinct malformation syndromes, arising from the same initial mutation, remain unclear. Gorry et al have cited an identical mutation (ala344gly) in FGFR2 in Crouzon and Jackson-Weiss syndromes as an example of the same phenomenon.

Crouzon syndrome, which is clinically differentiated from these other syndromic forms of craniosynostosis by the degree of proptosis, maxillary hypoplasia, and the absence of limb malformations, has now been associated with over 30 mutations at the FGFR2 locus, missense, splice site, and small in frame deletions. Mutations are located in both the first and second half of the third immunoglobulin-like domain, and the non-random pattern of mutations has been discussed elsewhere. Although the range of FGFR2 mutations associated with Crouzon syndrome has been broad, the original linkage data showed no evidence of heterogeneity. To date, analysis of the FGFR2 locus has identified mutations in approximately 66% of our Crouzon syndrome cohort of 70 patients, none of whom had acanthosis nigricans.

One of the less common associations seen in a subgroup of patients with Crouzon syndrome is acanthosis nigricans. This velvety hyperplasia of the skin, with accentuation of skin markings and hyperpigmentation, is usually found on the neck, axillae, and other flexural regions of the body, but acanthosis nigricans is, in general, recognised to be clinically heterogeneous. Although uncommon, the association with Crouzon syndrome is clear, 11 such cases having been identified by Koizumi et al. These authors drew attention to some atypical features of the Crouzon associated acanthosis nigricans, specifically the early onset of the pigmentation and the unusual distribution of the affected skin, particularly involving the perioral region.

Mutations within FGFR3 have been identified in discrete skeletal dysplasias. Four such conditions have now been causatively associated with FGFR3 mutations: achondroplasia, in which virtually all mutations are in the transmembrane region of the receptor, hypochondroplasia, in which there are two mutations in the tyrosine kinase domain, and thalidomide dysplasia types I and II (TDI and II). TDI, in which the femora are curved, has been described in association with missense mutations involving creation of a cysteine in the linker region between immunoglobulin-like domains 2 and 3 and read through mutations of the stop codon. Type II, characterised by relatively long and straight femora, has been described in association with a tyrosine kinase domain mutation.
A recurrent mutation, ala391glu, causes Crouzon syndrome and acanthosis nigricans

Figure 1  Postoperative appearance of case 1. Note the mild facial asymmetry and perioral acanthosis nigricans (A) and the flexural skin thickening and acanthosis nigricans (B). (All photographs reproduced with permission.)

(K650E) of FGFR3. As both types may be associated with the severe skull malformation, clover leaf skull, TDI I and II represent evidence that FGFR3 mutations may also have craniosynostosis clinically. We now extend the association between FGFR3 mutations and craniosynostosis by reporting a single specific mutation, ala391glu, in the transmembrane region of FGFR3 in three unrelated patients with Crouzon syndrome and acanthosis nigricans. This is only 11 amino acids away, within the transmembrane domain, from the predominant mutation causing achondroplasia.

Patients and methods

CASE 1

This male patient (fig 1) was born to clinically normal parents following a normal pregnancy and delivery. Birth weight, head circumference, and other clinical parameters were normal. Proptosis and skull malformation were evident from birth and craniosynostosis was confirmed radiologically. Motor and intellectual development have been normal and the craniosynostosis has been managed surgically. At the age of 14 years, he was referred to a dermatologist (CM) with a history of dry skin on the face since the age of 9. Clinical examination showed extensive acanthosis nigricans of the axilla, neck, and, to a lesser extent, the groin. The periorbital and perioral skin was prominently affected but there was no palmo-plantar or mucosal involvement. There was generalised skin thickening, particularly over the trunk. In addition several small, wart-like acanthomas were noted, as were several melanocytic naevi on the face and upper trunk.

CASE 2

This female patient was born to clinically normal parents (fig 2). The early clinical course was dominated by problems with feeding and failure to thrive. Incomplete choanal atresia led to associated respiratory difficulties. Her head circumference was on the 50th centile, disproportionately large for her height and weight, which were both below the 3rd centile. There was proptosis clinically and skull x ray confirmed premature bicornal synostosis at the age of 8 months. There was midface hypoplasia and surgical correction of the craniofacial malformations was performed at the age of 10 months. Motor and intellectual development were normal. Reviewed dermatologically at the age of 6 years (JPE), there was a notable degree of thickening of the skin around the neck and fossae. Velvety thickening and hyperpigmentation, characteristic of acanthosis nigricans, were seen on the neck, axillae, antecu-

Figure 2  Mild asymmetry and perioral acanthosis nigricans in case 2 (A). Note the acanthosis nigricans over the neck (B).
logical involvement was striking. There were no other abnormalities and a recent blood sugar evaluation was normal.

**PCR ANALYSIS**

DNA was extracted from lymphocytes by salting out. Primers amplifying the entire transmembrane domain of FGFR3 from genomic DNA were used as previously published. A 164 bp product results.

The primer sequences 5'AGGAGCTGGTGAGGCTGA-3' and 5'BioGGAGATCGTTGTGCACGGTG-3' were designed to amplify the entire transmembrane domain of FGFR3 from genomic DNA. PCR conditions were 200 ng of genomic DNA, 10 mmol.l⁻¹ Tris, pH 8.3, 1.5 mmol.l⁻¹ MgCl₂, 50 mmol.l⁻¹ KCl, 200 μmol.l⁻¹ dNTP, 0.7 μmol l⁻¹ α³²P-dCTP, 50 pmol of each primer, and 0.5 U Taq polymerase in a final volume of 50 μl; 30 cycles of 94°C × 30 seconds, 64°C × 30 seconds, 72°C × 40 seconds.

**RESTRICTION DIGESTION**

PCR products were purified by phenol/chloroform ethanol precipitation and restriction digestion was performed according to the manufacturer's specifications (New England Biolabs). Resolution of fragment products was performed on a 3% agarose gel.

**DNA SEQUENCING**

PCR products were sequenced directly by including a single 5' biotinylated primer in the PCR reaction. PCR products were then captured and immobilised to Dynabeads M280 streptavidin (Dynal). This was followed by denaturation using 0.15 mol/l NaOH and sequencing using α³²P-dATP and the Sequenase kit (Amersham).

**Results**

Sequencing showed a point mutation in the patients compared to the normal control and published sequence (fig 4). The C-A mutation was predicted to destroy a AciI restriction site. The normal fragment sizes generated following AciI digestion of the 164 bp PCR fragment is 17 bp, 24 bp, 57 bp, and 66 bp while fragment sizes generated following restriction of PCR products from affected chromosomes of patients were predicted to be 24 bp, 57 bp, and 83 bp. Following PCR amplification of the affected subjects, products were digested with AciI and the resulting fragments resolved on a 3% agarose gel (fig 5). All three affected subjects showed the 83 bp fragment while the normal controls showed the wild type restriction pattern. The parents of case 1 showed the normal wild type pattern, confirming the de novo nature of his mutation. Similarly, the affected daughter of case 3 also shares his mutation.

**Discussion**

The data we present confirm that Crouzon syndrome with acanthosis nigricans represents a clinically and genetically distinct subgroup among patients with Crouzon syndrome, as reported by Myers et al. Together these data,
in a total of seven patients, all showing acanthosis nigricans in addition to Crouzon features, represent the first evidence of locus heterogeneity within the Crouzon syndrome patient group. That the mutation is causative is confirmed by the de novo observation in case 1 and the identification of the identical mutation in the affected daughter of case 3.

The amino acid change, which results in the substitution of a charged for a non-charged residue, is only 11 amino acids away from the predominant mutation (G380R), in the transmembrane region of FGFR3, found in achondroplasia. As both mutations involve creation of an additional positive charge, correct insertion of the molecule into the membrane is likely to be hindered.

FGFR3 and FGFR2 have quite different patterns of expression during organogenesis, so it is somewhat surprising that mutations in both genes should give rise to such similar effects on the suture of the skull. It further means that the explanation of the mode of action should probably include other factors whose pattern of expression reflects more closely the tissues affected. Possible candidates are the proteoglycans, which are required as a third component in the activation of FGFRs by FGFs, and whose composition is likely to vary in different types of cartilage.

In general FGFR3 the expression pattern is more restricted than that of FGFR1 and FGFR2. The most prominent expression is in prebone cartilage rudiments of all bones including flat bones of the skull and later in development in resting cartilage, a pattern which correlates well with the skeletal dysplasias resulting from several FGFR3 mutations, but is more difficult to explain in cases with only cranial involvement. As with FGFR1 and 2, the second half of the third immunoglobulin-like loop is encoded by one of two alternatively spliced exons. The IIIb form, equivalent to KGFR in FGFR2, is expressed in mouse skin and epidermal keratinocytes so it seems likely that this splice form may be responsible for the acanthosis nigricans.

As a clinical sign, acanthosis nigricans is frequently observed with syndromes of insulin resistance, such as Berardinelli lipodystrophy and mutation involving the insulin receptor gene. Significantly, there is no evidence of disturbed glucose metabolism in any of our cases.

In keeping with the observations of Koizumi et al. in Crouzon syndrome related acanthosis nigricans, the skin stigmata in our three cases showed the atypical age of onset and unusual distribution, including perioral involvement, which seemingly characterises this condition.

The phenotype is still unexpected and it remains to be seen whether other Crouzon cases, without the acanthosis nigricans, will be found to have FGFR3 mutations or whether, as might be predicted, the outstanding Crouzon related mutations are located elsewhere in the FGFR2 gene.

This work was funded by the Wellcome Trust and the Medical Research Council.

A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans.

D Wilkes, P Rutland, L J Pulleyn, W Reardon, C Moss, J P Ellis, R M Winter and S Malcolm

doi: 10.1136/jmg.33.9.744

Updated information and services can be found at:
http://jmg.bmj.com/content/33/9/744

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/